drugset
drugset / Trial / NCT05738434

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

NCT05738434 ↗

Phase 2 Recruiting 188 enrolled The First Affiliated Hospital of Zhengzhou University
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line

Timeline

Start
2023-03-02
Primary completion
2025-09-01
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 250 mg Oral
Background Camrelizumab Monoclonal antibody 200 mg Intravenous
Background Cisplatin Other / unclassified 25 mg/m2 Intravenous
Background Paclitaxel Small molecule 135 mg/m2 Intravenous
Background Paclitaxel Small molecule 150 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Paclitaxel Small molecule 180 mg/m2 Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous

Indications

digestive system carcinoma